• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MEDTRONIC HEART VALVES DIVISION MOSAIC AORTIC BIOPROSTHETIC HEART VALVE; HEART-VALVE, NON-ALLOGRAFT TISSUE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MEDTRONIC HEART VALVES DIVISION MOSAIC AORTIC BIOPROSTHETIC HEART VALVE; HEART-VALVE, NON-ALLOGRAFT TISSUE Back to Search Results
Model Number 305U
Device Problem Gradient Increase (1270)
Patient Problem Valvular Stenosis (2697)
Event Date 10/25/2016
Event Type  Injury  
Manufacturer Narrative
Product analysis: the product specimen has been returned for analysis; however, the evaluation is still in progress.Conclusion: upon conclusion of the product analysis and investigation, a supplemental report will be submitted.
 
Event Description
Medtronic received information that 1 year and 8 months post implant of this bioprosthetic valve, a transesophageal echocardiogram (tee) showed increased gradients and moderate stenosis.One year and 11 months post implant, the patient presented with a mean gradient of 56mmhg.The physician explanted and replaced the device with a non-medtronic product.No further adverse patient effects were reported.
 
Manufacturer Narrative
Product analysis: upon receipt at medtronic¿s quality laboratory, the valve appeared slightly distorted with one stent post deflected.All leaflets were stiff due to host tissue on the outflow.Tears on the tunica of the right and non-coronary cusps adjacent to the inflow margin of attachment appeared to be associated to the removal of host tissue during explant.The tunica of the left cusp appeared intact.The free margins of the non-coronary and left cusps folded back, adhering to the host tissue on the outflow.All commissures appeared intact.A long remnant of glistening off white pannus lined the inflow margin of attachment adjacent to the non-coronary cusp extending slightly into the non-coronary left inferior coaptive area, and 1 to 2 mm onto the non-coronary cusp showing a possible reduced inflow orifice area.Traces of pannus were observed on the outflow.An unknown amount of pannus appeared to have been removed on the inflow during explant.Tan thrombotic appearing host tissue filled and stiffened all leaflets on the outflow.Brown discoloration in the tunica along the inflow margin of attachment extending to the tissue and base stitching suggested prior hemorrhage or blood accumulation.Radiography showed no evidence of mineralization in the valve and/or host tissue.Conclusion: the pannus overgrowth on the inflow appeared to have extended several millimeters out onto the leaflet which would have significantly impaired the leaflet mobility.The impairment of leaflet mobility may have led to the thrombus formation on the outflow of the valve causing the high gradient / stenosis.In addition, distortion of the annular ring can restrict the leaflets from fully opening and potentially causing the high gradient.Pannus overgrowth is associated with surgical valve replacement due to patient interaction and/or healing response with the surgical valve.There are many studies which discuss the etiology of pannus.Pannus formation is patient dependent based on the possible underlying cause.Chronic pannus formation may be precipitated by an immune response to the bioprosthetic valve sewing ring and /or sutures and size of the bioprosthesis.It may also be caused by the presence of an injured endothelial surface potentially releasing fibroblast growth factor-2, blood flow turbulence, pregnancy and /or inadequate anti-coag ulation.The time of pannus formation after valve implantation varies; studies have reported time frames from 6-12 months.The ingrowth of the tissue may gradually affect the function of the valve leaflets.Pannus overgrowth has been an inherent risk of surgical valve replacement and is addressed in the current risk management file.
 
Manufacturer Narrative
If information is provided in the future, a supplemental report will be issued.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
MOSAIC AORTIC BIOPROSTHETIC HEART VALVE
Type of Device
HEART-VALVE, NON-ALLOGRAFT TISSUE
Manufacturer (Section D)
MEDTRONIC HEART VALVES DIVISION
1851 e deere ave
santa ana CA 92705
Manufacturer (Section G)
MEDTRONIC HEART VALVES DIVISION
1851 e deere ave
santa ana CA 92705
Manufacturer Contact
paula bixby
8200 coral sea street ne
mounds view, MN 55112
7635055378
MDR Report Key6393294
MDR Text Key69555428
Report Number2025587-2017-00376
Device Sequence Number1
Product Code LWR
UDI-Device Identifier00613994760593
UDI-Public00613994760593
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P990064
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,health
Reporter Occupation Physician
Type of Report Initial,Followup,Followup
Report Date 04/14/2017
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received03/09/2017
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date12/07/2015
Device Model Number305U
Device Catalogue Number305U227
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer02/21/2017
Is the Reporter a Health Professional? Yes
Date Manufacturer Received04/14/2017
Was Device Evaluated by Manufacturer? Yes
Date Device Manufactured12/27/2010
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age79 YR
Patient Weight85
-
-